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ABSTRACT  
Cyclophosphamide-based regimens are front-line treatment for numerous pediatric 
malignancies, however current dosing methods result in considerable interpatient variability in 
tumor response and toxicity.  In this pediatric population, our objectives were to 1. quantify and 
explain the pharmacokinetic variability of cyclophosphamide, and two of its metabolites, 
hydroxycyclophosphamide (HCY) and carboxyethylphosphoramide mustard (CEPM); 2. apply a 
population pharmacokinetic model to describe the disposition of cyclophosphamide and these 
metabolites.  A total of 196 blood samples were obtained from 22 children with neuroblastoma 
receiving intravenous (IV) cyclophosphamide (400 mg/m2/day) and topotecan.  Blood samples 
were quantitated for concentrations of cyclophosphamide, HCY and CEPM using liquid 
chromatography-mass spectrometry and analyzed using nonlinear mixed effects modeling with 
NONMEM software system.  After model building was complete, the area under the 
concentration-time curve (AUC) was computed using NONMEM.  Cyclophosphamide 
elimination was described by noninducible and inducible routes with the latter producing HCY.  
Glomerular filtration rate (GFR) was a covariate for the fractional elimination of HCY and its 
conversion to CEPM.  Considerable interpatient variability was observed in the AUC of 
cyclophosphamide, HCY and CEPM.  These results represent a critical first step in developing 
pharmacokinetic-linked pharmacodynamic studies in children receiving cyclophosphamide to 
determine the clinical relevance of the pharmacokinetic variability in cyclophosphamide and its 
metabolites.
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INTRODUCTION 
Cyclophosphamide is the cornerstone of curative chemotherapy regimens in over 50% 
of newly diagnosed pediatric cancer patients.  Dose intensification of cyclophosphamide is 
associated with improved outcome in many of these patients, but is also associated with 
increased adverse drug reactions (ADRs).  The pressing need for improving the safety of 
cyclophosphamide is highlighted by the impact of a minor dosing modification to the VAC 
(vincristine/dactinomycin/cyclophosphamide) regimen leading to unexpected increase in ADRs 
in children less than 3 years old.1  Thus, there is a need to delineate factors in 
cyclophosphamide metabolism that may impact both response and ADRs to cyclophosphamide-
based combination chemotherapy regimens.  In adults, there is substantial interpatient 
variability in the cyclophosphamide area under the plasma concentration-time curve (AUC), and 
an even greater variability in the AUC of its metabolites when cyclophosphamide is dosed 
based on body surface area (BSA) or weight.2, 3  Children have more rapid cyclophosphamide 
clearance normalized to BSA (i.e., ml/min/m2) relative to adults, although the mechanism is 
unidentified.4-8  
Cyclophosphamide predominantly undergoes hepatic elimination, with 25% (range 5-
30%) of an IV dose excreted unchanged in the urine.3  A major fraction of cyclophosphamide 
dose (70%) is metabolized to hydroxycyclophosphamide (HCY) by multiple cytochrome P450 
enzymes.3  A minor fraction of cyclophosphamide dose (5%) is metabolized to 
dechloroethylcyclophosphamide (DCCY) by CYP3A4/5.9  The metabolite HCY exists in 
equilibrium with its tautomer–aldophosphamide, and the concentrations of these two 
metabolites are assayed together.10  HCY undergoes intracellular transport, subsequently 
releasing phosphoramide mustard which covalently cross-links DNA.  Phosphoramide mustard 
does not readily cross cell membranes and thus makes the transport of HCY critical.3  
Hydroxycyclophosphamide is metabolized by aldehyde dehydrogenase 1A1 (ALDH1A1) to 
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nontoxic carboxyethylphosphoramide mustard (CEPM).3  CEPM is the predominant urinary 
metabolite of cyclophosphamide.3   
A substantial challenge in seeking a better understanding of cyclophosphamide 
pharmacokinetics and pharmacodynamics has been the difficulty in quantitating HCY plasma 
concentrations.10  HCY is extremely unstable in biologic fluids (in vitro half-life in plasma < 3 
minutes) and only recently have more clinically applicable methods been developed.11-14  These 
methods are accurate, sensitive and specific and have since provided reliable tools to advance 
our understanding of the pharmacokinetic/dynamics of cyclophosphamide and its metabolites in 
predominantly adult patients receiving myeloablative dose cyclophosphamide prior to 
hematopoietic cell transplantation.2, 15-19  In this study, we sought to be the first to characterize 
HCY pharmacokinetics and to develop a population pharmacokinetic model of 
cyclophosphamide, HCY, and CEPM in children receiving multiple daily doses of 
cyclophosphamide.    
 
METHODS 
Patient population.  Twenty-two children (17 male and 5 female) were included in this study.  
The pharmacokinetics were evaluated after the first cycle of fractionated non-myeloablative 
dose cyclophosphamide with topotecan, administered under a limited institution pilot protocol, 
ANBL02P1 which was conducted by the Children’s Oncology Group (Duarte, CA).  Institutional 
Review Board approval was obtained at each individual participating institution, specifically 
Children’s Hospital and Regional Medical Center (Seattle, WA), Children’s Memorial Hospital 
Medical Center at Chicago (Chicago, IL), St. Jude Children’s Research Hospital (Memphis, TN) 
and University of California San Francisco (San Francisco, CA).  Children from the Children’s 
Hospital at Westmead could participate in the clinical trial but were excluded from the 
cyclophosphamide pharmacokinetic study due to the extended time period (i.e., >48 hours (h)) 
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necessary to transport the plasma samples from Australia to the United States.  Prior to study 
conduct, parental written informed consent was obtained for all children and written assent for 
those children over 7 years of age was obtained.  
All children were diagnosed with neuroblastoma or ganglioneuroblastoma and had no 
prior systemic therapy.  All children had adequate renal (i.e., serum creatinine < 1.5 mg/dL, and 
creatinine clearance or radioisotope glomerular filtration rate (GFR) > 60 ml/min/1.73 m²) and 
liver (i.e., total bilirubin < 1.5 mg/dL and alanine aminotransferase < 300 units/L) function.  Prior 
to chemotherapy administration, radioisotope GFR was determined using each individual 
institution’s procedures. 
Chemotherapy regimen.  Cyclophosphamide was infused through a central venous access 
catheter over 30 minutes at a dose of 400 mg/m2/day in those children weighing greater than 12 
kilograms or 13.3 mg/kg/day in those children weighing 12 kilograms or less.  The body weight 
and BSA used to calculate doses were based on individual institutional guidelines.  
Cyclophosphamide was administered daily for 5 days.  Cyclophosphamide doses were not 
adjusted based on pharmacokinetic data.  Immediately after each cyclophosphamide infusion 
was completed, a 30-minute topotecan infusion began and was repeated daily after each dose 
of cyclophosphamide.  Topotecan doses were pharmacokinetically targeted after doses 1 and 3.  
The success of topotecan targeting and clinical response will be reported in a separate 
manuscript.   
Cyclophosphamide pharmacokinetic sampling and analysis.  The blood volume for 
cyclophosphamide pharmacokinetic analysis was limited by the young age of the patient 
population and the blood volume needed for pharmacokinetically targeting topotecan doses.  
Cyclophosphamide pharmacokinetic blood samples were drawn from the lumen not used to 
infuse the cyclophosphamide dose.  Pharmacokinetic blood samples were drawn immediately 
before, upon completion of the 30-minute infusion, and at 3, 6, and 24 h after the start of the first 
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and fourth cyclophosphamide infusions.  The volume of blood drawn was 1 mL for the first four 
samples and 2 mL for the fifth sample (i.e., 24 h post infusion).   
The sample processing procedures were derived from those developed in hematopoietic 
cell transplant recipients.13, 14  Aliquots of each sample were placed into tubes containing either 
phenylhydrazine for analysis of HCY or ethylenediaminetetraacetic acid for analysis of 
cyclophosphamide and CEPM.  The tubes were inverted 3 to 4 times, stored at 4°C for a 
maximum of 1 h and centrifuged.  The supernatant was then decanted and stored at -70°C 
within 1 h of sample collection.   
All samples were shipped on dry ice to our laboratory within 3 months.  
Cyclophosphamide, HCY, and CEPM concentrations in plasma were quantitated separately 
using the methods of Kalhorn et al13, 14 with minor modifications as described in Table 1.  In the 
case of CEPM, negative ion detection at m/z 293 was used.  This ion, although lesser in 
abundance, has a lower incidence of background interference, allowing for more sensitive 
detection of CEPM.  The HCY-phenylhydrazine derivative was detected in the negative ion 
mode as the chloride adduct at m/z 401.14   
Population Pharmacokinetic Modeling.  Given the small number of blood samples available 
in each subject, nonlinear mixed effects modeling was used to describe this pharmacokinetic 
dataset.  The nonlinear mixed effects approach explicitly models the time course of the data and 
the hierarchical statistical variability which is present among subjects and within subjects. 
Pharmacokinetic models of cyclophosphamide metabolism were fit to all pharmacokinetic data 
(i.e., cyclophosphamide, HCY and CEPM) from all patients simultaneously by use of the first-
order method in the nonlinear mixed-effects modeling software NONMEM (version V, double 
precision).20  Between-subject variability (BSV) of parameters was modeled by use of a 
lognormal model.  Residual unknown variability (RUV) was estimated by use of additive models 
for cyclophosphamide and CEPM and a combination of proportional and additive errors for 
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HCY.  Individual parameters were calculated by use of the POSTHOC option (empirical Bayes 
estimates) of NONMEM.  A nominal significance level of 0.05 (linked to a difference in objective 
function value of at least 3.86 points for one additional parameter) was assumed to aid in 
covariate model selection. 
 The pharmacokinetic model framework we used is depicted in Figure 1 and its 
components have been previously described.18, 21  The definition of the different parameters of 
this model is explained in Table 3.  This integrated model simultaneously describes the 
pharmacokinetics of cyclophosphamide, HCY and CEPM and includes autoinduction of 
cyclophosphamide to HCY.  The concentrations are expressed in µmol/L of cyclophosphamide 
(with molecular weight 261.1 g/mol), HCY (277.1 g/mol) and CEPM (293 g/mol).  Because the 
model, expressed as a system of four differential equations, is by definition a “mass balance” 
equation, the modeling is performed in mass units (mg/m2) and the amounts are converted to 
µmol/L for comparison with data.  Similarly, the EC50 is reported in µmol/L of cyclophosphamide, 
but is converted within the model to mass units. 
Elimination of cyclophosphamide is described via a noninducible route and an inducible 
route, with the latter leading to HCY formation.  Autoinduction of HCY formation was modeled 
by use of a hypothetic enzyme compartment as described previously.19, 21-23  The inducible 
clearance was proportional to the amount of enzyme in this compartment.  The “initial” inducible 
clearance is defined as the inducible clearance at time 0.  The enzyme followed a zero-order 
formation that was enhanced by cyclophosphamide with a maximum fold of induction (Emax)–
type relationship and first-order degradation. The initial amount of enzyme was set to a 
dimensionless value of 1 at time 0. 
The initial structural model (Figure 1), with three compartments for cyclophosphamide 
(CY) and metabolites HCY and CEPM as well as a fourth enzyme compartment to model the 
inducible clearance, was as described in Qiu and Yao et al21 and in Salinger et al.19   
 7
)()(
)(
)()()()(
)(
)(
)(
)(
1
)(
)()()(
)(
4334
4
334321
3
2
1
50
1
2
211
1
tAKtAK
dt
tdA
tAKtAKtAtA
V
CL
dt
tdA
tAK
V
tA
EC
tA
V
E
K
dt
tdA
tAtA
V
CL
tA
V
CL
dt
tdA
CEPM
HCY
CY
IND
ENZ
CY
CY
MAX
ENZ
CY
IND
CY
NON
⋅−⋅=
⋅−⋅−=
⋅−
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+
+=
−−=
 
where the concentrations of cyclophosphamide, HCY and CEPM are 
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parameters are described in Figure 1 and Table 3.  The model departed from that of Qiu and 
Yao et al21 in the following ways.  First, doses were based upon BSA rather than body weight 
(see “Chemotherapy Regimen” section above).  In those two children whose cyclophosphamide 
dose was based upon weight, the actual dose (mg) administered was divided by that patient’s 
BSA.  Weight and BSA are correlated in this pediatric population (r2=0.97), and thus we would 
expect similar results using weight-normalized dosing.  Second, we made no assumption 
regarding the influence of the covariate age upon the base model.  Third, the volume of 
distribution of HCY (VHCY) and CEPM (VCEPM) were both assumed based on our previous 
experience with cyclophosphamide modeling in hematopoietic cell transplant recipients.21, 23.  In 
our previous cyclophosphamide modeling, VHCY and VCEPM could not be estimated23 and a value 
of 1 L was assumed for adults.21, 23  The average BSA in the original hematopoietic cell 
transplant population cyclophosphamide pharmacokinetic model was 1.76 m2,21 and thus VHCY 
and VCEPM were assumed equal to 1 L/1.76 m2 (0.57 L/m2).   
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 As a validation of the model, we performed a visual predictive check wherein data were 
simulated for 4400 subjects (200 for each of the 22 measured covariate sets) using the final 
population pharmacokinetic model and the median and 90% prediction intervals plotted with the 
original data. 
Statistical Analysis.   
Generalized estimating equations were used to evaluate the association of AUC with 
independent variables that included age, sex, BSA, GFR and day of CY administration.  Each 
analysis was done separately for the AUCs of CY, HCY, and CEPM.  SAS Version 9.1 (Cary, 
NC) was used for all statistical analyses. 
 
RESULTS 
Patient Population.  Of the 22 patients studied, 17 were male and 5 were female.  At the time 
of diagnosis, the median age was 3.16 years (range: 1.30 – 9.37).  At the time of 
cyclophosphamide infusion, the BSA was 0.62 m2 (range:  0.45 – 1.47), actual body weight was 
14.2 kg (range:  8.7 – 52.8), and GFR was 117 ml/min/1.73m2 (range:  78 – 238).   
Quantitation of cyclophosphamide and metabolites.  Twenty two and twenty patients, 
respectively, had pharmacokinetic sampling after the first and fourth cyclophosphamide dose.  
Cyclophosphamide and CEPM concentrations were detectable in 167 (85%) and 128 (65%), 
respectively, of 196 samples.  HCY required separate bedside processing, and was detectable 
in 113 of 196 (58%) samples.  The majority of samples which were below the limit of detection 
were the 24 h samples, despite obtaining 2 ml of blood in an effort to improve our ability to 
quantitate cyclophosphamide, HCY and CEPM.  Of the 29 samples drawn at 24 h, no analytes 
could be quantitated in 23 samples, 5 had one analyte that was detectable and 1 was drawn 
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after the subsequent dose was given (the latter of which was deleted from population 
pharmacokinetic modeling). 
Population pharmacokinetic modeling.  In Model 1 (see Table 2), we started by assuming a 
value for VCEPM = VHCY = 0.57 L/m2 and allowed the remaining pharmacokinetic parameters (i.e., 
CLIND, CLNON, VCY, KHCY, KENZ, K34 and KCEPM) to be estimated relative to this assumption. 
Estimates of most of the parameters, other than K34 and KHCY, were unaffected by the choice of 
VCEPM and VHCY value.  The reported values of K34 and KHCY should be considered as “relative” to 
these volume assumptions. 
 Various alternative models were evaluated, and the results are summarized in Table 2. 
Model 2 evaluated the actual dose administered, not normalized for BSA – essentially testing 
removal of BSA as a covariate.  In this model the fixed volumes (VCEPM = VHCY = 0.57 L/m2) were 
multiplied by the mean subject BSA of 0.681 m2 to convert to units of liters (L).  While this 
conversion may not be optimal, the clear underperformance of Model 2, as measured by 
increased objective function value (OFV), did not warrant further investigation. 
 In Model 3, we replaced the fixed-effects model for parameter VCY with a mixed-effects 
model with lognormal random effect.  This resulted in a highly significant improvement in OFV 
(i.e., decrease of 73.2 points) versus Model 1. 
 Using Model 3, we performed a covariate analysis by visual assessment of plots and by 
regressions of the seven individually varying parameter values (CLIND, CLNON, VCY, KHCY, KENZ, 
K34 and KCEPM) and the corresponding random effects with the available covariates (i.e., age, 
gender, weight, BSA, and pre treatment GFR).  The three most-promising parameter-covariate 
relationships were KHCY vs. GFR (r2=0.31, p=0.004), K34 vs. GFR (r2=0.25, p=0.01), and CLNON 
vs. gender (r2=0.13, p=0.05).  We tested each of these by postulating a linear relationship 
between parameters and covariates in Models 4, 5 and 6, respectively.  Models 4 and 5 both 
showed significant (p < 0.05) improvement in OFV versus Model 3, while Model 6 did not.  
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Model 7 included linear functions of GFR for both KHCY and K34.  This resulted again in a 
significant improvement over both Models 4 and 5 (at p < 0.05), and provided the final model.  
The final parameter estimates are summarized in Table 3.  Figure 2 shows plots of observed vs. 
population predicted (PRED) and individually predicted (IPRED) concentrations of 
cyclophosphamide, HCY and CEPM for the final model. 
 Figure 3 provides model validation in the form of a visual predictive check.  The median 
and 90% prediction intervals were plotted with the original data for cyclophosphamide and its 
metabolites HCY and CEPM after the first and fourth dose.  The visual predictive check shows 
generally good agreement between model and data.  That fact that fewer than 10% of data 
points lie outside the 90% prediction interval might indicate a slight overestimation of the 
variability.  While this may be a consequence of the relatively small dataset, it is more likely the 
result of employing only a diagonal model covariance matrix.  However, the data did not support 
estimation of parameter covariances. 
AUC of cyclophosphamide, HCY and CEPM in children.  The final model (Model 7) was 
applied to compute the AUC of cyclophosphamide, HCY and CEPM after each of the five 
cyclophosphamide doses.  The resulting AUCs for cyclophosphamide, HCY and CEPM are 
shown in Figure 4 and provided in Table 4 for the whole patient population.  Figure 5 contains 
examples of the pharmacokinetic model fit for two patients to the cyclophosphamide, HCY and 
CEPM concentration-time data. 
 Considerable interpatient variability was observed in cyclophosphamide AUC (i.e., 2.9 
fold variability after dose 1 and 3.0 fold variability after dose 4).  For the AUC of 
cyclophosphamide, the median was 431 µM*h (range: 258-746) on day 1 and 313 µM*h (range: 
171-510) on day 4.  The cyclophosphamide AUC was associated with age (p=0.03), BSA 
(p=0.028), and day of administration (p=0.0001).  The cyclophosphamide clearance, calculated 
based on the AUCs in Table 4, was 3.58 L/h/m2 (range: 1.73-5.53) after dose 1 and 4.86 L/h/m2 
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(range:  1.93-7.37) after dose 4 (Table 5).  Model-predicted initial inducible clearance (i.e., the 
clearance value extrapolated to before the first dose, without circulating cyclophosphamide) was 
1.77 L/h/m2.   
 In comparison to cyclophosphamide AUC, there was greater variability in the AUC of 
HCY and CEPM (i.e., 3.8-6.0 fold variability).  For the AUC of HCY, the median was 26.8 µM*h 
(range: 11.4-63.8) on day 1 and 37.0 µM*h (range: 17.3-66.4) on day 4.  The HCY AUC was 
associated with GFR (p=0.031), and day of administration (p<0.0001).   For the CEPM AUC, the 
median was 16.5 µM*h (range: 9.3-38) on day 1 and 23.3 µM*h (12.7-76.6) on day 4.  The 
CEPM AUC was associated with day of administration (p=0.0032).  There was negligible 
correlation (i.e., all R2<0.039) between AUCCY and AUCHCY after dose 1 or after dose 4 and 
between AUCCY and AUCCEPM after dose 1 or after dose 4. 
 
DISCUSSION 
This manuscript is the first to report considerable pharmacokinetic variability of the 
plasma concentrations of HCY in children receiving daily nonmyeloablative cyclophosphamide.  
Hydroxycyclophosphamide is transported intracellularly to release the active metabolite 
phosphoramide mustard, and thus may be a key determinant in the efficacy and toxicity of 
cyclophosphamide-containing regimens.  Quantitation of the other cyclophosphamide 
metabolites was not feasible because of the limited blood volume per sample.  This manuscript 
is also the first describing a population pharmacokinetic model of cyclophosphamide, HCY, and 
CEPM in children.  The key findings of this pediatric study include the presence of considerable 
interpatient variability of cyclophosphamide AUC and its metabolites and the development of a 
population pharmacokinetic model with covariates to predict these AUCs.  The population 
pharmacokinetic model identified baseline GFR as a covariate of HCY elimination rate and 
CEPM formation rate.  By reducing unexplained variability, covariate identification can reduce 
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the need for pharmacokinetic sampling, thereby facilitating the development of a limited 
sampling schedule feasible for adequately sized pharmacokinetic and pharmacodynamic 
studies.  This work represents an essential step in advancing our understanding of risk factors 
for poor response or severe ADRs to cyclophosphamide in pediatric cancer patients. 
Cyclophosphamide-based combination chemotherapy regimens are used to treat the 
majority of children with cancer.  Traditional dosing methods based on single covariates, such 
as BSA, do not necessarily address the presence of variability sufficiently well.25, 26  The natural 
first step in obtaining an improved understanding of pharmacodynamic variability is to evaluate 
the interpatient variability in the systemic exposure of the parent drug and relevant metabolites.  
This is the main contribution of these results; however there are additional potential benefits.  
Specifically, pharmacokinetic-linked pharmacodynamic studies are hindered by the need for 
intense blood sampling schedules, and in the case of HCY, bedside processing.  A population 
pharmacokinetic model provides a rigorously quantitative approach to incorporate population 
information (i.e., typical values and variability of drug disposition, together with explanatory 
covariates) in the determination of an individual’s systemic exposure and can reduce the need 
for individual-specific information.  Population pharmacokinetics can potentially be used to 
simultaneously describe the concomitant role of demographic covariates (e.g., age), and clinical 
covariates (e.g., GFR).  Improved understanding of the determinants of variability can then lead 
to improved trial design.  While the awareness of these issues has increased for drugs in the 
development phase, there is a still strong need to improve dosing for drugs that are already in 
use, such as cyclophosphamide.  Understanding the sources of variability in young patients is of 
the utmost importance to optimize exposure to anti-tumor chemotherapy to ultimately achieve 
the maximum disease response with non-lethal toxicity.  In addition, a population 
pharmacokinetic model facilitates development of an improved limited sampling schedule, which 
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could decrease the needed blood volume and resource intensity of pharmacokinetic-linked 
pharmacodynamic trials.27   
Cyclophosphamide clearance agrees with the previously published values in pediatric 
populations (Table 5), suggesting that topotecan does not influence cyclophosphamide 
elimination.4, 6-8  Similarly, the autoinduction of cyclophosphamide clearance (resulting in 
decreased AUC for subsequent doses) agreed with previous reports.17, 28-30  In addition, the 
current convention of dosing children less than 12 kg on a mg/kg basis (i.e., patients 2 and 19) 
appears to yield a comparable AUC to those larger children (i.e., >12 kg) who receive 
cyclophosphamide 400 mg/m2 (Table 4).  The latter point is critically important, as children 
younger than 3 years of age experienced increased ADRs after what was anticipated to be a 
minor dosing modification to the VAC (vincristine/dactinomycin/cyclophosphamide) regimen.1  
These pharmacokinetic data, along with the accompanying population pharmacokinetic model, 
represent initial steps towards the goal of optimizing cyclophosphamide dosing in such young 
children.   
Using analytical methods developed for pharmacodynamic studies in myeloablative 
hematopoietic cell transplant patients (Table 1), we are the first to describe the 
pharmacokinetics of HCY in children.  The interpatient variability in the AUC of HCY was 
substantial, that is 5.6 fold after dose 1 and 3.8 fold after dose 4 (Table 4).  A similar trend was 
found in the AUC of CEPM (Table 4).  In contrast to the reports of Yule et al that some children 
had no detectable CEPM concentration,4, 5, 7, 8 we were able to estimate the AUC of CEPM in all 
patients (Table 5) due to the increased sensitivity of our analytical method (Table 1) and the use 
of a population pharmacokinetic model (Figure 1).  Notably, there was a weak correlation 
between the AUC of CY and the AUC of its metabolites, in agreement with previous reports.12, 16, 
17, 31, 32  This suggests that the cyclophosphamide clearance (as AUC = dose/clearance) cannot 
be used to predict metabolite exposure as has been suggested.8, 33, 34   
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This is the first population pharmacokinetic model of cyclophosphamide and metabolite 
disposition in young children, specifically less than 10 years of age (i.e., 1.30 – 9.37 years).  The 
majority of the population pharmacokinetic models were presumably (i.e., age not reported)35 or 
were exclusively from36 populations older than 10 years of age.  However, our initial population 
pharmacokinetic model of cyclophosphamide in hematopoietic cell transplant patients receiving 
myeloablative dose cyclophosphamide (60 mg/kg/day × 2 days) with total body irradiation 
(CY/TBI) did include eight children whose age were less than 10 years old.21 In the CY/TBI 
population, age was the only covariate which improved model fitting and was inversely 
correlated with the noninducible clearance (CLNON) of cyclophosphamide.21  In agreement with 
this finding, the CLNON in the neuroblastoma patients was higher (i.e., 1.13 L/hr calculated from 
1.83 L/h/m2 × 0.62 m2 median patient BSA) than that observed in the CY/TBI conditioned 
patients (i.e., 0.665 L/hr calculated from 0.00899 L/hr/kg21 × the mean patient body weight of 74 
kg in that dataset).  However, age was not a covariate for CLNON (Tables 2 and 3) within the 
narrow age range (i.e., < 10 years) of this neuroblastoma population.  Regarding the initial 
inducible clearance of cyclophosphamide (CLIND), the CLIND was 1.11 L/h (1.79L/h/m2 × 0.62 m2 
median patient BSA).   This is lower than previously reported values from adult populations, 
which range from 2.11 L/h21 (i.e., 0.0286 L/h/kg × the mean patient body weight (74 kg) in that 
dataset) and 2.91 L/h.15, 35  This suggests that the relative contribution of the CLIND is lower in 
children, although further data are needed to confirm this finding.  The remaining parameters 
compare favorably with population pharmacokinetic models of cyclophosphamide and its 
metabolites in adult populations.  For example, the pediatric pharmacokinetic analysis provides 
a value of 46.5/h for KHCY, which is the HCY elimination rate.  This large value can be perceived 
as suggesting a very rapid elimination, however, it is less than previously published values for 
adults from our group (i.e., 147/h)19, 21 and others (i.e., 118 to 169/h).35, 37 The assumed values 
of VHCY and VCEPM are in accordance with previous reports, as we have remarked in the results 
section.   
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GFR was a covariate for the fractional elimination of HCY and its conversion to CEPM 
(Tables 2 and 3).  Further studies are needed to confirm these findings, as a physiologic 
rationale for GFR being a covariate with these two parameters is currently elusive.  CEPM is the 
predominant urinary metabolite after cyclophosphamide administration and its AUC was 
dramatically higher in an anephric child.38  The conversion of HCY to CEPM is mediated by 
hepatic aldehyde dehydrogenase.  This model predicted the individual and population 
concentrations well (Figure 2).  It also allows for calculation of modeled AUCs of 
cyclophosphamide, HCY and CEPM after each of the five cyclophosphamide doses (Figures 3 
and 4) while obtaining pharmacokinetic blood samples after dose 1 and 4 only.  This population 
pharmacokinetic model needs to be validated in a separate pediatric population, especially due 
to our limited ability to quantitate all three analytes in many of the 24h samples.  We plan to 
validate this model in a separate cohort of children receiving non-myeloablative dose 
cyclophosphamide and subsequently create an optimal limited sampling schedule to conduct 
pharmacokinetic and pharmacodynamic studies in children.  Identifying pharmacodynamic 
relationships in future studies could lead to personalized cyclophosphamide dosing to achieve a 
target AUC to improve efficacy or decrease toxicity.  We are currently employing this approach 
after myeloablative cyclophosphamide dosing in hematopoietic cell transplant recipients.   
Pharmacodynamic studies are needed to determine the clinical relevance of this 
interpatient variability in the pharmacokinetics.  Quantitation of cyclophosphamide and CEPM 
concentrations allowed for comparison to historical cyclophosphamide pharmacokinetic data 
within pediatric patients.  It is also important to quantitate CEPM concentrations because 
elevated CEPM AUC is associated with a higher risk of liver toxicity in hematopoietic cell 
transplant recipients receiving myeloablative dose CY/TBI.2  Quantitation of HCY was critical, as 
its pharmacokinetics has been reported in only one anephric child to date.38  The majority of 
pharmacodynamic studies with cyclophosphamide and its metabolites have been conducted in 
patients receiving myeloablative cyclophosphamide for conditioning prior to hematopoietic cell 
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transplantation.2, 15, 31  In this population, the pharmacodynamics of cyclophosphamide and its 
metabolites differ based on the conditioning regimen.31  In those receiving 
busulfan/cyclophosphamide, the AUC of cyclophosphamide, HCY and CEPM are not related to 
toxicity or response.31  However, in patients receiving CY/TBI, an elevated AUC of CEPM is 
associated with a higher risk of liver toxicity.2  This has led to ongoing studies of targeting 
cyclophosphamide doses based on the AUC of CEPM in hopes of lowering toxicity while 
maintaining the AUC of HCY in hopes of maintaining engraftment rates.18  These results 
suggest that the concentration – effect relationships may differ between combination 
chemotherapy regimens and thus, future pharmacokinetic and pharmacodynamic studies 
should be conducted in homogeneous disease populations treated with the same combination 
chemotherapy regimen.  The development to this population pharmacokinetic model of 
cyclophosphamide and its metabolites is an integral step in improving the efficacy and toxicity of 
cyclophosphamide -based regimens in pediatric cancer patients.  Despite its widespread use for 
over fifty years, there are still uncertainties regarding the optimal dose of cyclophosphamide as 
shown by the increased rate of ADRs after a minor dosing modification to the VAC from mg/kg 
to mg/m2 dosing of vincristine/dactinomycin/cyclophosphamide in young children.1  This 
pharmacokinetic data, along with the accompanying population pharmacokinetic model, are first 
steps in determining if there are select populations of children which may need different 
cyclophosphamide doses.  In addition, the creation of a limited sampling schedule – which is 
essential for pharmacokinetic-pharmacodynamic children in infants and toddlers – may be 
possible after validation of this population pharmacokinetic model.  A limited sampling schedule 
will greatly facilitate recruitment of enough children to conduct pharmacokinetic and 
pharmacodynamic studies, which are desperately needed in hopes of improving the efficacy of 
cyclophosphamide. 
 In conclusion, we have shown substantial interpatient variability in the pharmacokinetics 
of cyclophosphamide and its metabolites in children.  Topotecan administration did not appear 
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to affect the clearance of cyclophosphamide.  The development of a population pharmacokinetic 
model with relevant covariates will provide a framework to evaluate the pharmacodynamics of 
cyclophosphamide, with the long-range goal of improved prediction of an individual child’s 
response and/or ADRs of cyclophosphamide-based regimens in this population.  
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 Table 1.  Quantitation of cyclophosphamide and metabolites by liquid chromatography-mass spectrometry 
 
Limit of detection Analyte Matrix Sample preparation Charge/ 
Ion FHCRC Yule et al4-8   
Cyclophosphamide 150 µL plasma Protein precipitation 
1.ml acetonitrile 
 
Positive/ 
261 
0.6 µM13 1 µM 
HCY 500 µL whole blood +  
1 mL phenylhydrazine 
 
Solid phase extraction 
 
Negative/ 
401 
0.25 µM14 Not assessed 
CEPM 100 µL plasma Protein precipitation 
150 µL acetonitrile 
Negative/ 
293 
0.25 µM14 3 µM 
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Table 2.  Alternative models evaluated for cyclophosphamide, HCY and CEPM 
 
Model Model description Result OFV 
1 Initial model Proper convergence and covariance estimation only with 
excellent starting values 
1152.2 
2 Dose not normalized by BSA Inferior model 1394.0 
3 Added random component to VCY in Model 1 Significantly decreased OFV, decreased variability (both 
BSV and RUV) and improved precisions 
1079.0 
4 Model 3 but KHCY a linear model in GFR Decreased OFV and variability (both BSV and RUV) over 
Model 3 
1058.6 
5 Model 3 but K34 a linear model in GFR Decreased OFV and variability (both BSV and RUV) over 
Model 3 
1063.4 
6 Model 3 but CLNON a linear model in gender No improvement over Model 3.  Gender provides no 
predictive value 
1079.0 
7 Both KHCY and K34 linear models in GFR Significantly improved OFV (over Models 3, 4 and 5). Final 
model 
1041.6 
OFV, minimum value of objective function.  BSV, Between-subject variability. RUV, Residual unknown variability
Table 3.  Estimates of population pharmacokinetic parameters of model for cyclophosphamide (CY), HCY and CEPM 
       
Parameter Designation (units) Estimate 
(SE%) 
BSV (%) CY HCY CEPM 
Volume of distribution of CY VCY (L/m2) 13.1 (5.1) 17.8    
Noninducible clearance of CY CLNON (L·h-1·m-2) 1.83 (30.6) 61.7    
Initial inducible clearance of CY CLIND (L·h-1·m-2) 1.79 (28.2) 65.7    
Enzyme degradation rate KENZ (h-1) 6.57E-3(55.3) 126    
Volume of distribution of HCY VHCY (L/m2) 0.57, fixed     
HCY elimination rate KHCY = α + β·(GFR-GFR*)/GFR* (h-1) 35.9    
    - typical value at median GFR α (h-1) 47.0  (20.9)     
    - change in KHCY per unit GFR from median β (h-1) -26.6 (36.8)     
K34, CEPM formation rate from HCY K34 = a + b·(GFR-GFR*)/GFR* (h-1) 20.3    
    - typical value at median GFR a (h-1) 0.331 (9.2)     
    - change in K34 per unit GFR from median b (h-1) -0.234 (14.1)     
Volume of distribution of CEPM VCEPM (L/m2) 0.57, fixed     
CEPM elimination rate KCEPM (h-1) 0.447 (16.0) 38.1    
CY concentration of half-maximal induction EC50 (μmol/L) 0.6, fixed     
Maximum induction EMAX 5, fixed     
Residual error       
    Proportional error (%)     24.7  
    Additive error (μmol/L)    6.2 0.295 0.389 
GFR is glomerular filtration rate (ml/min/1.73 m2).  GFR* is the median GFR (i.e., 117 ml/min/1.73 m2). 
 
 21
Table 4.  The AUC of cyclophosphamide (CY) and its metabolites on day 1 and 4 of cyclophosphamide administration 
 
 Age  Weight BSA GFR Dose 
AUC of CY 
(µM*h) 
AUC of HCY 
(µM*h) 
AUC of CEPM 
(µM*h) 
ID (Yr) Sex (kg) (m2) (ml/min/1.73 m2) mg/kg mg/m2 Day 1 Day 4 Day 1 Day 4 Day 1 Day 4 
1 1.93 M 15.6 0.67 125  400 357 254 18.4 27.4 12.4 18.5 
2 1.30 M 8.7 0.45 238 13.3 257 569 510 36.5 50 9.3 13.4 
3 3.22 M 14.7 0.63 145  400 461 291 24.9 37.6 11.3 17.1 
4 5.51 F 13.3 0.61 148  400 487 286 43.8 56.1 21.8 28 
5 3.53 F 13.6 0.63 109  400 582 393 22.4 36.8 10.5 17.3 
6 1.83 F 12.8 0.54 78  400 591 348 29.5 34.6 23.9 28.3 
7 3.10 M 15.1 0.63 116  400 643 380 25.8 38.5 18.1 27.9 
8 3.43 M 12.4 0.58 112  400 746 404 40.7 51.7 20 25.4 
9 3.48 M 15.3 0.68 190  400 468 344 36.8 61.6 16.8 28.3 
10 9.02 M 52.8 1.47 141  400 277 209 27 33.9 14.5 18.2 
11 1.89 M 14.4 0.57 78  400 317 246 11.4 17.3 9.8 14.9 
12 8.36 F 24.3 0.91 99  400 611 316 27.3 34.3 13.9 17.6 
13 2.26 M 12.7 0.57 101  400 282 234 40.2 42.3 38.8 40.9 
14 2.49 M 12.5 0.57 158  400 541 441 25.5 37.6 16.1 24 
15 9.37 M 32.9 1.14 100  400 399 278 17.9 23.8 13 17.4 
16 2.46 M 18.1 0.73 161  400 400 224 26.6 32.8 10.3 12.7 
17 3.24 M 18.6 0.74 173  400 280 209 47.7 56 19.2 22.6 
18 2.41 M 14 0.6 115  400 363 309 19.4 24.2 23.6 29.9 
19 1.44 F 9.7 0.48 110 13.3 269 258 171 20.3 23.4 13.1 15.1 
20 3.77 M 13.2 0.58 98  400 392 364 35.5 37.2 29.3 30.9 
21 2.55 M 13.3 0.6 134  400 354 326 63.8 66.4 23.6 24.6 
22 4.18 M 17.5 0.62 118  400 493 379 17.3 35.2 36.4 76.6 
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Table 5.  Comparison to previously reported pharmacokinetic results 
 
Author Subjects CY Dose (mg/m2) Timing CY Clearance 
(L/h*m2) 
Subjects with 
detectable  
CEPM AUC 
CEPM AUC 
(µM*h) 
Tasso 19924 9 125-1500 Variable 1.48 
(0.6–5.2) 
7 0.17c 
(ND–74.7) 
 
Yule 19955 36 368-2490 Variable NA 28 105c 
(ND–1210) 
 
Yule 19966 38 370-2490 Dose 1 2.9 
(1.2–106.1) 
 
NA NA 
Yule 20017 13 600-2000 Dose 1 3.1 
(1.4–6.2) 
11 99 
(ND–274) 
 
Yule 20048 36 300-1000 Dose 1 3.6 
(2.1–5.4) 
8 ND 
(ND–206) 
 
McCune 2008 22 400 Dose 1 3.58  
(1.73–5.53)  
 
22 16.5 
(9.3-38) 
   Dose 4 4.86 
(1.93–7.37) 
20 23.3 
(12.7–76.6) 
 
Figure 1.  Metabolic schema for cyclophosphamide (CY), HCY and CEPM 
CEPM
CY
ENZ
HCY
Dose
CLNON
CLIND
KHCY
KCEPM
K34
KENZ
KENZ*(1+Emax*CCY/(EC50+CCY))
VCY
VHCY
VCEPM
 
See Table 3 for explanation of the parameters (and final modeled values).  Note, the inducible 
enzyme formation rate depends on the modeled (time varying) concentration of 
cyclophosphamide CCY. 
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Figure 2.  Observed vs. Population Predicted (PRED) and Individually Predicted (IPRED) 
concentration (μM) of cyclophosphamide, HCY and CEPM.*   
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*Population Predicted (PRED) are predictions using population-level parameter values 
(Table 3).  Individually Predicted (IPRED) are predictions using individual-level parameter 
values (not reported).  Solid lines have slope=1. Data points denoted with a □ were BQL. 
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Figure 3.   Model validation via a visual predictive check: observed data is compared with 
median prediction and 90% prediction intervals from 4400 subjects simulated from the 
final model. 
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Figure 4.  Modeled cumulative and 24 hour interval AUC for cyclophosphamide, HCY and 
CEPM plotted for each individual.  The curves show the mean AUC.   
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Figure 5.  Concentration-Time profiles and simulations of cyclophosphamide (CY), HCY 
and CEPM for two study patients.  Data points represented by a □ were BQL and have 
been set to QL/2. 
24 48 72 96 120
0
20
40
60
80
hours
μM
CY Concentration  (ID= 10 )
24 48 72 96 120
0
20
40
60
80
100
120
hours
μM
CY Concentration  (ID= 22 )
24 48 72 96 120
0
2
4
6
8
10
12
14
hours
μM
HCY Concentration  (ID= 10 )
24 48 72 96 120
0
2
4
6
8
10
hours
μM
HCY Concentration  (ID= 22 )
24 48 72 96 120
0
1
2
3
4
hours
μM
CEPM Concentration  (ID= 10 )
24 48 72 96 120
0
2
4
6
8
hours
μM
CEPM Concentration  (ID= 22 )
 
 28
References 
1. Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor 
for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and 
cyclophosphamide. J Clin Oncol. May 15 2004;22(10):1894-1901. 
2. McDonald GB, Slattery JT, Bouvier ME, et al. Cyclophosphamide metabolism, liver 
toxicity, and mortality following hematopoietic stem cell transplantation. Blood. 2003 Mar 
1;101(5):2043-2048. 
3. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Clinical pharmacokinetics of 
cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135-1164. 
4. Tasso MJ, Boddy AV, Price L, Wyllie RA, Pearson AD, Idle JR. Pharmacokinetics and 
metabolism of cyclophosphamide in paediatric patients. Cancer Chemother Pharmacol. 
1992;30(3):207-211. 
5. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide metabolism in children. Cancer 
Res. 1995;55(4):803-809. 
6. Yule SM, Boddy AV, Cole M, et al. Cyclophosphamide pharmacokinetics in children. Br J 
Clin Pharmacol. 1996;41(1):13-19. 
7. Yule SM, Price L, Cole M, Pearson AD, Boddy AV. Cyclophosphamide metabolism in 
children following a 1-h and a 24-h infusion. Cancer Chemother Pharmacol. 
2001;47(3):222-228. 
8. Yule SM, Price L, McMahon AD, Pearson AD, Boddy AV. Cyclophosphamide 
metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res. Jan 15 
2004;10(2):455-460. 
9. Ren S, Yang JS, Kalhorn TF, Slattery JT. Oxidation of cyclophosphamide to 4-
hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver 
microsomes. Cancer Res. 1997;57(19):4229-4235. 
10. Baumann F, Preiss R. Cyclophosphamide and related anticancer drugs. J Chromatogr B 
Biomed Sci Appl. Nov 25 2001;764(1-2):173-192. 
11. Anderson LW, Chen TL, Colvin OM, et al. Cyclophosphamide and 4-
Hydroxycyclophosphamide/Aldophosphamide Kinetics in Patients Receiving High-Dose 
Cyclophosphamide Chemotherapy. Clin Cancer Res. 1996;2(9):1481-1487. 
12. Chen TL, Kennedy MJ, Anderson LW, et al. Nonlinear pharmacokinetics of 
cyclophosphamide and 4- hydroxycyclophosphamide/aldophosphamide in patients with 
metastatic breast cancer receiving high-dose chemotherapy followed by autologous 
bone marrow transplantation. Drug Metab Dispos. 1997;25(5):544-551. 
13. Kalhorn TF, Ren S, Howald WN, Lawrence RF, Slattery JT. Analysis of 
cyclophosphamide and five metabolites from human plasma using liquid 
chromatography-mass spectrometry and gas chromatography- nitrogen-phosphorus 
detection. J Chromatogr B Biomed Sci Appl. 1999;732(2):287-298. 
14. Kalhorn TF, Howald WN, Cole S, et al. Rapid quantitation of cyclophosphamide 
metabolites in plasma by liquid chromatography-mass spectrometry. J Chromatogr B 
Analyt Technol Biomed Life Sci. May 1 2006;835(1-2):105-113. 
15. de Jonge ME, Huitema AD, Tukker AC, van Dam SM, Rodenhuis S, Beijnen JH. 
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically 
guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose 
chemotherapy. Clin Cancer Res. Jan 1 2005;11(1):273-283. 
16. Slattery JT, Kalhorn TF, McDonald GB, et al. Conditioning regimen-dependent 
disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow 
transplantation patients. J Clin Oncol. May 1996;14(5):1484-1494. 
 29
17. Ren S, Kalhorn TF, McDonald GB, Anasetti C, Appelbaum FR, Slattery JT. 
Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow 
transplantation patients. Clin Pharmacol Ther. Sep 1998;64(3):289-301. 
18. McDonald GB, McCune JS, Batchelder A, et al. Metabolism-based cyclophosphamide 
dosing for hematopoietic cell transplant. Clin Pharmacol Ther. Sep 2005;78(3):298-308. 
19. Salinger DH, McCune JS, Ren AG, et al. Real-time dose adjustment of 
cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian 
pharmacokinetic approach. Clin Cancer Res. Aug 15 2006;12(16):4888-4898. 
20. Beal SL, Sheiner LB, Boeckmann AJE. NONMEM Users Guides. Elliott City, Maryland, 
USA.: Icon Development Solutions; 1989-2006. 
21. Qiu R, Yao A, Vicini P, et al. Diminishing the risk of nonrelapse mortality in 
hematopoietic stem cell transplantation: Prediction of exposure to the cyclophosphamide 
metabolite carboxyethylphosphoramide mustard. Clin Pharmacol Ther. Sep 
2004;76(3):270-280. 
22. Hassan M, Svensson US, Ljungman P, et al. A mechanism-based pharmacokinetic-
enzyme model for cyclophosphamide autoinduction in breast cancer patients. Br J Clin 
Pharmacol. 1999;48(5):669-677. 
23. Huitema AD, Mathot RA, Tibben MM, Rodenhuis S, Beijnen JH. A mechanism-based 
pharmacokinetic model for the cytochrome P450 drug-drug interaction between 
cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide. J 
Pharmacokinet Pharmacodyn. Jun 2001;28(3):211-230. 
24. Verbraecken J, Van de Heyning P, De Backer W, Van Gaal L. Body surface area in 
normal-weight, overweight, and obese adults. A comparison study. Metabolism. Apr 
2006;55(4):515-524. 
25. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and 
introduction of an alternative. J Clin Oncol. 1996;14(9):2590-2611. 
26. Baker SD, Verweij J, Rowinsky EK, et al. Role of body surface area in dosing of 
investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst. Dec 18 
2002;94(24):1883-1888. 
27. Panetta JC, Iacono LC, Adamson PC, Stewart CF. The importance of pharmacokinetic 
limited sampling models for childhood cancer drug development. Clin Cancer Res. Nov 1 
2003;9(14):5068-5077. 
28. Graham MI, Shaw IC, Souhami RL, Sidau B, Harper PG, McLean AE. Decreased 
plasma half-life of cyclophosphamide during repeated high- dose administration. Cancer 
Chemother Pharmacol. 1983;10(3):192-193. 
29. Moore MJ, Hardy RW, Thiessen JJ, Soldin SJ, Erlichman C. Rapid development of 
enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther. 
1988;44(6):622-628. 
30. Fasola G, Lo Greco P, Calori E, et al. Pharmacokinetics of high-dose cyclophosphamide 
for bone marrow transplantation. Haematologica. Mar-Apr 1991;76(2):120-125. 
31. McCune JS, Batchelder A, Deeg HJ, et al. Cyclophosphamide following Targeted Oral 
Busulfan as Conditioning for Hematopoietic Cell Transplantation: Pharmacokinetics, 
Liver Toxicity, and Mortality. Biol Blood Marrow Transplant. Jul 2007;13(7):853-862. 
32. Sladek NE, Doeden D, Powers JF, Krivit W. Plasma concentrations of 4-
hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given 
high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer 
Treat Rep. Oct 1984;68(10):1247-1254. 
33. Ayash LJ, Wright JE, Tretyakov O, et al. Cyclophosphamide pharmacokinetics: 
correlation with cardiac toxicity and tumor response. J Clin Oncol. Jun 1992;10(6):995-
1000. 
 30
 31
34. Petros WP, Broadwater G, Berry D, et al. Association of high-dose cyclophosphamide, 
cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in 
patients with primary breast cancer. Clin Cancer Res. Mar 2002;8(3):698-705. 
35. de Jonge ME, Huitema AD, Beijnen JH, Rodenhuis S. High exposures to bioactivated 
cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver 
following high-dose chemotherapy. Br J Cancer. May 8 2006;94(9):1226-1230. 
36. Joerger M, Huitema AD, Richel DJ, et al. Population pharmacokinetics and 
pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a 
study by the EORTC-PAMM-NDDG. Clin Pharmacokinet. 2007;46(12):1051-1068. 
37. de Jonge ME, Huitema AD, Rodenhuis S, Beijnen JH. Integrated Population 
Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual 
drug-drug interaction. J Pharmacokinet Pharmacodyn. Apr 2004;31(2):135-156. 
38. McCune JS, Adams D, Homans AC, Guillot A, Iacono L, Stewart CF. Cyclophosphamide 
disposition in an anephric child. Pediatr Blood Cancer. Jan 2006;46(1):99-104. 
 
 
